ESTRO 37 Abstract book

ESTRO 37 CONTENT

SATURDAY 21 APRIL 2018

Teaching Lecture Radiation-induced cardiac toxicity: what have we learnt?. ........................................................ (Abs. 1) Measuring the systemic immune-modulated effect of radiation.................................................. (Abs. 2) Optimal sequence in the treatment of breast cancer: RT first?................................................... (Abs. 3) Standard of care in the treatment of bladder cancer................................................................ (Abs. 4) Brachytherapy improvement calls for improved imaging........................................................... (Abs. 5) Incorporating radiomic parameters into predictive models: methods for variable selection............. (Abs. 6) Dual energy CT in radiotherapy: principles and potential.......................................................... (Abs. 7) Patient involvement and shared decision making..................................................................... (Abs. 8) Symposium Partial organ treatments to minimise late radiation effects................................................... (Abs. 9-12) Radiotherapy combined with immunotherapy: mechanisms and biomarkers......................... (Abs. 13-16) More of both? Breast reconstruction and regional lymph node irradiation!............................ (Abs. 17-19) Current issues in the treatment of muscle-invasive bladder cancer...................................... (Abs. 20-22) Do we need adjuvant vaginal BT in endometrial cancer?.................................................... (Abs. 23-25) Is radiomics going to deliver on the promises that dose painting made?. ............................. (Abs. 26-29) Is dose calculation in proton therapy clinical practice a solved problem?.............................. (Abs. 30-32) Patient centered care and monitoring side effects: Review clinics and follow up.................... (Abs. 33-35) Poster Viewing Poster viewing 1: Lung................................................................................................. (Abs. 36-44) Symposium Improving radiation therapy in breast cancer by avoiding side effects.................................. (Abs. 45-48) Proffered Papers RB 1: Joint efforts in Immuno-radiobiology...................................................................... (Abs. 49-55) CL 1: Genitourinary..................................................................................................... (Abs. 56-62) CL 2: Health services research to improve value and access. ............................................. (Abs. 63-69) BT 1: Gynaecological brachytherapy............................................................................... (Abs. 70-76) PH 1: Dosimetry.......................................................................................................... (Abs. 77-83) PHY 2: Treatment planning in particle therapy. ................................................................ (Abs. 84-90) RTT 1: Innovative strategies for improving patient care..................................................... (Abs. 91-97) Poster Viewing Poster viewing 2: Upper GI..........................................................................................(Abs. 98-106) Presidential Symposium Presidential symposium................................................................................................... (Abs. 107) Award Lecture Emmanuel van der Schueren Award Lecture....................................................................... (Abs. 108) Symposium Lung and dose escalation........................................................................................... (Abs. 109-112) Blood borne biomarkers............................................................................................. (Abs. 113-115) Joint Symposium ESTRO-ASTRO: The art and science of head and neck radiotherapy.................................. (Abs. 116-119) ESTRO-ESGO: State of the art: new ESGO-ESTRO-ESP guidelines on management of cervical cancer.............................................................................. (Abs. 120-123) Symposium Quality assurance in brachytherapy............................................................................. (Abs. 124-126) Multi-parametric functional imaging for patient classification, RT personalisation and response monitoring........................................................................................... (Abs. 127-129) Why is fully automated image segmentation and deformable image registration not here yet?................................................................. (Abs. 130-132) Brachytherapy - RTT advanced roles............................................................................ (Abs. 133-135) Poster Viewing Poster viewing 3: Dosimetry. ..................................................................................... (Abs. 136-144) Symposium How to minimise toxicity in pelvic malignancies in the era of precision radiotherapy........... (Abs. 145-148) Proffered Papers RB 2: Biomarkers..................................................................................................... (Abs. 149-154) CL 3: Breast............................................................................................................ (Abs. 155-161)